GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, Zepbound — are the most talked-about medical intervention of the decade. Prescriptions have increased by over 300% since 2021. The weight loss results, for many people, are real. But as a functional medicine doctor for hormone imbalance who has spent more than 30 years helping patients achieve sustainable metabolic health, I want to have an honest conversation about what GLP-1 drugs actually do, what they do not do, and why the patients who need them most are often the ones for whom they work least well — or stop working entirely.
What GLP-1 Drugs Actually Do
GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut in response to eating. It signals the pancreas to release insulin, suppresses glucagon, slows gastric emptying, and signals the brain that you are full. GLP-1 receptor agonists mimic and amplify this signal, producing powerful appetite suppression and improved blood sugar regulation. The mechanism is legitimate and the short-term results are often impressive. For patients with type 2 diabetes or severe obesity, GLP-1 drugs represent a meaningful clinical advance. The cardiovascular outcome data is genuinely compelling.
What GLP-1 Drugs Do Not Do
They do not fix the underlying hormone imbalances driving weight gain. Thyroid dysfunction, cortisol dysregulation, estrogen dominance, progesterone deficiency, testosterone decline, and insulin resistance are the root causes of weight gain in most women over 40. GLP-1 drugs suppress appetite and improve insulin signaling — but they do not address the thyroid, the adrenals, the sex hormones, or the metabolic dysfunction that created the problem in the first place.
They do not preserve muscle mass. Studies show that 25 to 40% of weight lost on GLP-1 drugs is lean muscle mass, not fat. For women in perimenopause who are already losing muscle due to declining testosterone and estrogen, this is a significant problem. Muscle is metabolically active tissue — losing it slows the resting metabolic rate and makes weight maintenance after stopping the drug extremely difficult.
They do not work long-term without lifestyle change. The majority of patients who stop GLP-1 drugs regain most of the weight within 12 months. This is a predictable biological response when the underlying drivers of weight gain have not been addressed. And they do not work as well in the presence of significant hormone dysregulation — patients with unaddressed thyroid dysfunction, severe cortisol dysregulation, or significant estrogen dominance have a substantially blunted response to GLP-1 therapy.
The Hormone Imbalances That GLP-1 Drugs Cannot Fix
Thyroid dysfunction is the most common missed diagnosis in women with weight gain. A normal TSH does not rule out functional hypothyroidism — and a patient with unaddressed hypothyroidism will lose weight more slowly on GLP-1 therapy and regain it more rapidly after stopping. Cortisol dysregulation drives visceral fat storage through mechanisms entirely independent of GLP-1 signaling — and GLP-1 drugs do not lower cortisol. Estrogen dominance, epidemic in perimenopausal women, is a significant driver of weight gain that GLP-1 drugs do not affect. And testosterone deficiency causes muscle loss and metabolic slowing that GLP-1 drugs cannot reverse — in fact, the muscle loss associated with GLP-1 therapy may be amplified in women with already-low testosterone.
What Functional Medicine Actually Looks Like for Metabolic Weight Gain
The functional medicine approach begins with a comprehensive diagnostic workup: full thyroid panel, DUTCH test for cortisol rhythm and sex hormone levels, fasting insulin and HOMA-IR for insulin resistance, comprehensive metabolic panel, and nutrient status. From this data, I build a personalized protocol that addresses the specific hormone imbalances driving each patient's weight gain. Optimizing thyroid function removes one of the most powerful brakes on metabolism. Restoring cortisol rhythm through adaptogenic support and sleep optimization reduces visceral fat accumulation. Balancing estrogen and progesterone reduces the hormonal drivers of fat storage. Restoring testosterone preserves and rebuilds lean muscle mass. And reversing insulin resistance through diet, resistance training, and targeted supplementation can produce durable results without pharmaceutical intervention in many patients.
Where GLP-1 Drugs Fit in a Functional Medicine Framework
I am not categorically opposed to GLP-1 drugs. For patients with significant obesity, cardiovascular risk, or type 2 diabetes, they can be a valuable tool. For patients who need a metabolic reset, short-term GLP-1 therapy combined with a comprehensive functional medicine protocol can produce excellent results. The key word is "combined." GLP-1 drugs used in isolation — without addressing the underlying hormone imbalances, without a structured nutrition and exercise protocol, and without a plan for preserving muscle mass — produce results that are temporary and often followed by rebound weight gain. The patients who achieve the most durable results are those who use GLP-1 therapy as a bridge while we simultaneously address the thyroid, cortisol, sex hormones, and lifestyle factors that created the metabolic dysfunction in the first place. That is what a root-cause approach to weight loss actually looks like.
— Dr. Jay Wrigley, NMD